The Impact of Advanced Glycation End-Products (AGEs) on Proliferation and Apoptosis of Primary Stem Cells: A Systematic Review
Open Access
- 14 November 2020
- journal article
- review article
- Published by Wiley in Stem Cells International
- Vol. 2020, 1-13
Abstract
Stem cell-based regenerative therapies hold great promises to treat a wide spectrum of diseases. However, stem cell engraftment and survival are still challenging due to an unfavorable transplantation environment. Advanced glycation end-products (AGEs) can contribute to the generation of these harmful conditions. AGEs are a heterogeneous group of glycated products, nonenzymatically formed when proteins and/or lipids become glycated and oxidized. Our typical Western diet as well as cigarettes contain high AGEs content. AGEs are also endogenously formed in our body and accumulate with senescence and in pathological situations. Whether AGEs have an impact on stem cell viability in regenerative medicine remains unclear, and research on the effect of AGEs on stem cell proliferation and apoptosis is still ongoing. Therefore, this systematic review provides a clear overview of the effects of glycated proteins on cell viability in various types of primary isolated stem cells used in regenerative medicine.Keywords
Funding Information
- Fonds Wetenschappelijk Onderzoek (1502120N, 12U7718N, 1154120N, 16NI05BOF)
- Hasselt University (1502120N, 12U7718N, 1154120N, 16NI05BOF)
This publication has 93 references indexed in Scilit:
- The effects of low-dose Nepsilon-(carboxymethyl)lysine (CML) and Nepsilon-(carboxyethyl)lysine (CEL), two main glycation free adducts considered as potential uremic toxins, on endothelial progenitor cell functionCardiovascular Diabetology, 2012
- The Promise and Perils of Stem Cell TherapeuticsCell Stem Cell, 2012
- Advanced glycation end products impair the migration, adhesion and secretion potentials of late endothelial progenitor cellsCardiovascular Diabetology, 2012
- Same or Not the Same? Comparison of Adipose Tissue-Derived Versus Bone Marrow-Derived Mesenchymal Stem and Stromal CellsStem Cells and Development, 2012
- Advanced glycation end products induce chemokine/cytokine production via activation of p38 pathway and inhibit proliferation and migration of bone marrow mesenchymal stem cellsCardiovascular Diabetology, 2010
- Rosiglitazone via upregulation of Akt/eNOS pathways attenuates dysfunction of endothelial progenitor cells, induced by advanced glycation end productsBritish Journal of Pharmacology, 2009
- JNK signaling in apoptosisOncogene, 2008
- Mitogen activated protein kinase inhibitors: where are we now and where are we going?Annals of the Rheumatic Diseases, 2006
- Evidence for stroke-induced neurogenesis in the human brainProceedings of the National Academy of Sciences, 2006
- Activation and signaling of the p38 MAP kinase pathwayCell Research, 2005